文献速递神经肿瘤小儿神经外科与脑积水

新诊断高级别脑干胶质瘤幼儿的放疗前强化诱导与骨髓清除性巩固化疗:「Head-Start」I 和 II 期临床试验报告

Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials.
PubMed 文献 · J Neurooncol · 2018-11-03

该研究报告了1991年至2002年间15例小于10岁的新诊断高级别脑干胶质瘤患儿接受「Head-Start」I 和 II 方案治疗的结果。方案包括4-5个周期强化诱导化疗后行一周期骨髓清除性化疗(塞替派、卡铂和依托泊苷)联合自体造血细胞 rescue。13例可评估患儿1年无事件生存率和总生存率分别为31%(95%CI 9-55%)和38%(95%CI 14-63%),中位无事件生存期和总生存期分别为6.6个月(95%CI 2.7-12.7)和8.7个月(95%CI 6.9-20.9)。作者结论为高级别脑干胶质瘤患儿未能从放疗前强化化疗策略中获益。

要点

  • 13例可评估患儿1年无事件生存率为31%(95%CI 9-55%)。
  • 13例可评估患儿1年总生存率为38%(95%CI 14-63%)。
  • 中位无事件生存期6.6个月(95%CI 2.7-12.7),中位总生存期8.7个月(95%CI 6.9-20.9)。

核心结论

  • 高级别脑干胶质瘤患儿未能从放疗前强化化疗策略中获益。

研究设计与样本

  • 1991年至2002年间,15例小于10岁的新诊断高级别脑干胶质瘤患儿接受「Head-Start」I 和 II 方案(HSI 和 HSII)治疗。
  • 治疗包括4-5个周期三种强化化疗方案之一的诱导化疗,随后行一周期骨髓清除性化疗(塞替派、卡铂和依托泊苷)联合自体造血细胞 rescue(AHCR)。
  • 6岁以上患儿或巩固化疗结束时存在残留肿瘤的患儿需接受放疗。

主要发现

  • 两例长期生存者回顾性发现为低级别胶质瘤,未纳入生存分析。
  • 13例可评估患儿1年无事件生存率为31%(95%CI 9-55%),1年总生存率为38%(95%CI 14-63%)。
  • 13例可评估患儿中位无事件生存期为6.6个月(95%CI 2.7-12.7),中位总生存期为8.7个月(95%CI 6.9-20.9)。
  • 8例患者在治疗期间出现疾病进展(7例在诱导化疗期间,1例在巩固化疗结束时)。
  • 10例患儿接受局部放疗,其中5例因残留肿瘤(3例在诱导化疗后,2例在巩固化疗后),5例因疾病进展。

局限性

  • 两例长期生存者回顾性发现为低级别胶质瘤,未纳入生存分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The dismal outcome in children with high-grade brainstem gliomas (BSG) accentuates the need for effective therapeutic strategies. We investigated the role of intensive, including marrow-ablative, chemotherapy regimens in the treatment of young children with newly-diagnosed high-grade BSG. METHODS: Between 1991-and-2002, 15 eligible children less than 10 years of age with a diagnosis of high-grade BSG were treated on "Head-Start" I and II protocols (HSI and HSII). Treatment included Induction with 4-5 cycles of one of three intensive chemotherapy regimens followed by Consolidation with one cycle of marrow-ablative chemotherapy (thiotepa, carboplatin and etoposide) with autologous hematopoietic cell rescue (AHCR). Irradiation was required for children over 6 years of age or for those with residual tumor at the end of Consolidation. RESULTS: We had two long-term survivors who were found retrospectively to harbor low-grade glial tumors and thus were not included in the survival analysis. Of the remaining 13 patients, the 1-year event-free (EFS) and overall (OS) survival for these children were 31% (95% CI 9-55%) and 38% (95% CI 14-63%), respectively. Median EFS and OS were 6.6 (95% CI 2.7, 12.7) and 8.7 months (95% CI 6.9, 20.9), respectively. Eight patients developed progressive disease during study treatment (seven during Induction and one at the end of Consolidation). Ten children received focal irradiation, five for residual tumor (three following Induction and two following Consolidation) and five due to disease progression. CONCLUSIONS: Children with high-grade BSG did not benefit from this intensive chemotherapy strategy administered prior to irradiation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Osorio DS, Patel N, Ji L, et al. Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials. J Neurooncol. 2018. PMID: 30392092. doi:10.1007/s11060-018-03003-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。